Home/ Stocks/ AARD

Aardvark Therapeutics, Inc. Common Stock

AARD XNAS

$7.70 -0.20 (-2.53%) ▼ 15-min delayed

Open

$7.76

High

$7.76

Low

$7.70

Volume

3.5K

Market Cap

$172.88M

About Aardvark Therapeutics, Inc. Common Stock

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 40 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-21,588,000	$-0.99
FY 2025	$0	$-57,591,000	$-2.93
Q3 2025	$1.35M	$-16,316,000	$-0.75
Q1 2025	$0	$-9,310,000	$-0.71

Related Market News

No specific coverage for AARD yet. Check out our latest market news or earnings calendar.

Get AARD Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Aardvark Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.